The mechanisms preventing the initial methylation and protecting against a repressive chromatin configuration are unknown, and their identification may help understand the key pathways affected in the majority of full-mutation patients and might ultimately lead to new therapeutic opportunities for restoring normal FMR1 expression levels in FXS patients [12, 24]. Here, FMR1 is linked to fragile X syndrome.